Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients

Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients

Alena Novakova-Jiresova,1 Katerina Kopeckova,2 Ludmila Boublikova,1 Renata Chloupkova,3 Bohuslav Melichar,4 Lubos Petruzelka,5 Jindrich Finek,6 Ondrej Fiala,6,7 Peter Grell,8 Stanislav Batko,2 Zdenek Linke,2 Igor Kiss,8 Jana Prausova,2 Tomas Buchler1 1Department of Oncology, First Faculty of Medicin...

Full description

Bibliographic Details
Main Authors:	Novakova-Jiresova A, Kopeckova K, Boublikova L, Chloupkova R, Melichar B, Petruzelka L, Finek J, Fiala O, Grell P, Batko S, Linke Z, Kiss I, Prausova J, Buchler T
Format:	Article
Language:	English
Published:	Dove Medical Press 2020-07-01
Series:	Cancer Management and Research
Subjects:	colorectal cancer regorafenib registry survival outcome analysis
Online Access:	https://www.dovepress.com/regorafenib-for-metastatic-colorectal-cancer-an-analysis-of-a-registry-peer-reviewed-article-CMAR

Similar Items

The use of regorafenib in colorectal cancer
by: Marina I Sekacheva, et al.
Published: (2019-06-01)

Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients
by: Pia S. Zeiner, et al.
Published: (2019-11-01)

Using of multi-kinase inhibitor regorafenib for metastatic colorectal cancer
by: O I Kit, et al.
Published: (2017-06-01)

Lupus-Like Glomerulonephritis Associated With Regorafenib, a Multikinase Inhibitor
by: Anna Strasma, et al.
Published: (2021-03-01)

Research advances in regorafenib in treatment of hepatocellular carcinoma
by: CHEN Weibo
Published: (2017-12-01)

Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study
by: Anant Ramaswamy, et al.
Published: (2019-01-01)

Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan
by: Kun-Huei Yeh, et al.
Published: (2021-11-01)

Prolonged Response to Regorafenib in a Patient with Iodine Refractory Thyroid Cancer
by: Selina K. Wong, et al.
Published: (2019-10-01)

The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice
by: Yoon SE, et al.
Published: (2018-12-01)

The role of regorafenib in the treatment of metastatic colorectal cancer
by: A A Tryakin
Published: (2016-06-01)

Targeting gastrointestinal stromal tumors: the role of regorafenib
by: Schroeder B, et al.
Published: (2016-05-01)

Regorafenib: from clinical research to clinical practice
by: M Yu Fedyanin, et al.
Published: (2017-09-01)

Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
by: Cheol-Hyung Lee, et al.
Published: (2020-07-01)

Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models
by: Dieter Zopf, et al.
Published: (2016-11-01)

Efficacy and safety of regorafenib versus dinutuximab with chemotherapy in Chinese children with neuroblastoma
by: Kun Dong, et al.
Published: (2019-02-01)

Efficacy and safety of regorafenib versus dinutuximab with chemotherapy in Chinese children with neuroblastoma
by: Kun Dong, et al.
Published: (2019-02-01)

Protein Kinase B and Extracellular Signal-Regulated Kinase Inactivation is Associated with Regorafenib-Induced Inhibition of Osteosarcoma Progression In Vitro and In Vivo
by: Po-Jung Pan, et al.
Published: (2019-06-01)

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer
by: Kawakami K, et al.
Published: (2019-10-01)

Regorafenib application in patients with metastatic colorectal cancer in actual clinical practice
by: M I Sekacheva, et al.
Published: (2016-09-01)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
by: Yuan-Hung Kuo, et al.
Published: (2021-05-01)

Effect of starting dose of regorafenib on overall survival of patients with metastatic colorectal cancer: a systematic review and meta-analysis
by: Mikhail Yu Fedyanin, et al.
Published: (2019-09-01)

Fatal Acute Liver Failure as a Consequence of Regorafenib Treatment in a Metastatic Colon Cancer
by: Dominique Béchade, et al.
Published: (2017-08-01)

Cross-Resistance of Acquired Radioresistant Colorectal Cancer Cell Line to gefitinib and regorafenib
by: Saeid Afshar, et al.
Published: (2020-01-01)

Regorafenib in Recurrent Glioblastoma Patients: A Large and Monocentric Real-Life Study
by: Giuseppe Lombardi, et al.
Published: (2021-09-01)

Long‐term survival of an advanced colorectal cancer patient treated with Regorafenib: Case report and literature review
by: Oronzo Brunetti, et al.
Published: (2019-12-01)

Regorafenib-loaded poly (lactide-co-glycolide) microspheres designed to improve transarterial chemoembolization therapy for hepatocellular carcinoma
by: Xiang Li, et al.
Published: (2020-11-01)

FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro
by: Yongjun Cha, et al.
Published: (2018-06-01)

Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report
by: Kenji Yoshino, et al.
Published: (2017-08-01)

Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
by: Wan Wang, et al.
Published: (2019-10-01)

Effect of Synchronous Versus Sequential Regimens on the Pharmacokinetics and Biodistribution of Regorafenib with Irradiation
by: Tung-Hu Tsai, et al.
Published: (2021-03-01)

Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells
by: Kazuaki Matsuoka, et al.
Published: (2018-09-01)

Berberine Sensitizes Human Hepatoma Cells to Regorafenib via Modulating Expression of Circular RNAs
by: Kunyuan Wang, et al.
Published: (2021-06-01)

Regorafenib Enhances Lethality of Sildenafil and Curcumin in Colorectal Cancer Cells
by: Owusu, Kervin Benjamin
Published: (2019)

Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications
by: Nicola Personeni, et al.
Published: (2018-06-01)

Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression
by: Jianliang Xu, et al.
Published: (2019-07-01)

Regorafenib Regulates AD Pathology, Neuroinflammation, and Dendritic Spinogenesis in Cells and a Mouse Model of AD
by: Kyung-Min Han, et al.
Published: (2020-07-01)

Inhibitory effects of regorafenib, a multiple tyrosine kinase inhibitor, on corneal neovascularization
by: Halil Ibrahim Onder, et al.
Published: (2014-04-01)

Hepatic arterial infusion chemotherapy plus regorafenib in advanced colorectal cancer: a real-world retrospective study
by: Cao, G., et al.
Published: (2022)

Efficacy and Safety of Regorafenib Monotherapy among Patients with Previously Treated Metastatic Colorectal Cancer in a Chinese Population: A Real-World Exploratory Study
by: Wang RT, et al.
Published: (2021-09-01)

CRISPR Loss-of-Function Screen Identifies the Hippo Signaling Pathway as the Mediator of Regorafenib Efficacy in Hepatocellular Carcinoma
by: Shigeki Suemura, et al.
Published: (2019-09-01)

Cannot write session to /tmp/vufind_sessions/sess_o8lu28nq5bgr2o5lpaib6v9vkg